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Description and comparison of Food and Drug
Administration-approved thoracic endovascular
aneurysm devices
Sean P. Lyden, MD, Cleveland, OhioIn 1991, endovascular aortic treatment was born as
Juan Parodi first described use of a stent graft to treat an
abdominal aortic aneurysm.1 Only 3 years later, Dake et al2
first described use of a homemade stent graft to treat
thoracic aneurysms.2 The development of minimally inva-
sive aneurysm treatment led to robust corporate research
and development. The culmination of early efforts aimed at
infrarenal aortic aneurysms (AAA) led to U.S. Food and
Drug Administration (FDA) approval of two devices in
1999 to treat AAAs. Unfortunately, research and develop-
ment for thoracic aneurysmal disease lagged behind ab-
dominal aortic endovascular devices. In 1998, the Gore
Excluder Thoracic device (W.L. Gore and Associates, Flag-
staff, Ariz) became the first device in theUnited States to be
studied for the feasibility of treatment of descending tho-
racic aortic aneurysms (TAAs).
Since 2005, we have seen three devices gain FDA
approval to treat descending TAAs in the United States: the
Gore TAG endograft, the Talent Thoracic endograft
(Medtronic AVE, Santa Rosa, Calif), and the Cook TX2
endograft (Cook, Bloomington, Ind). This article describes
the current devices approved to treat thoracic aortic pathol-
ogy and compares the differences among the devices. Trial
results are reviewed and compared in the article by Drs
Garcia-Toca and Eskandari.
GORE TAG THORACIC GRAFT
Device construct. The TAG graft is a self-expanding
endoprosthesis made of an expanded polytetrafluoroethyl-
ene (ePTFE) tube reinforced with ePTFE/fluorinated eth-
ylene propylene (FEP) film and an external nitinol self-
expanding stent along the entire graft (Fig 1). The stent is
attached to the graft with ePTFE/FEP bonding tape. A
circumferential PTFE sealing cuff is located on the external
surface of the endograft at the base of each flared, scalloped
end. The endoprosthesis contains radiopaque gold marker
bands at the base of the device flares approximately 1 cm
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10Sfrom each end of the endoprosthesis. An implantable
ePTFE/FEP sleeve is used to constrain the endoprosthesis
on the leading end of the delivery catheter. Unlacing of the
endoprosthesis initiates in the middle of the device and
simultaneously extends toward both ends of the endopros-
thesis (Fig 2). Endoprosthesis sizes range from 26 to 45
mm in diameter and 10, 15, and 20 cm in length.
Gore has sponsored several trials to evaluate the TAG
endograft. TAG 99-01 compared endovascular repair with
open surgical repair for repair of aneurysms of the descending
thoracic aorta. Enrollment began in September 1999 and was
completed in May 2001. After completion of enrollment in
TAG 99-01, fractures in the longitudinal wires were identi-
fied. Modifications were subsequently made to the device,
including removal of the longitudinal wire forms, addition of
a low permeability film, and modification of the sealing cuff
(Fig 1). The lowpermeability film added support to the device
to resist longitudinal compression.
The TAG 03-03 study confirmed that modification did
not affect the deployment of the device or the perioperative
performance. TAG 03-03 also found aneurysm sac enlarge-
ment5mm in only 4.5% of the test participants at 4 years,
compared with 21.6% of TAG 99-01 patients at 4 years.
This was most likely due to the addition of the low perme-
ability film layer to the device.
Since the original design, several other modifications of
the device have occurred. The olive tip of the device has
been modified to improve deliverability. Gore added a
45-mm device in 2010 and introduced a new sheath with a
pressurized hemostasis valve to minimize blood loss. The
TAG device has shown 5-year durability in successful aneu-
rysm exclusion, low risk of migration, rupture, and conver-
sion, and increased freedom from major adverse events
compared with open repair.
TALENT THORACIC STENT GRAFT
Device construct. The Talent Thoracic Stent Graft is
composed of a series of shaped, sinusoidal, self-expanding
nitinol wire rings, acting as springs, which are stacked in a
tubular arrangement to form a self-expanding nitinol struc-
ture. The proximal and distal springs of the stent graft are
connectedby a full-length connectingbar. The self-expanding
nitinol structure is covered by a monofilament polyester
woven graft. The graft material is sewn to the nitinol
structure, which securely incorporates the springs into the
graft. Figur8 radiopaque markers, made out of platinum-
iridium, are sewn to the graft to help visualize and identify
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ing bar, and the minimum overlap required when multiple
stent grafts are used (Fig 3). A bare support spring with five
wire peaks surrounding the proximal edge of the graft
material is also used in some configurations.
The proximal device is available in diameters of 22 to
46 mmwith a 2-mm increment. The covered lengths of the
proximal device range from 112 mm (largest diameter) to
116 mm (smallest diameter). The Talent distal device is a
tapered endograft system with a 4-mm difference in diam-
eter between the proximal and distal orifices. The distal
device is available in 22 to 44mm in 2-mm increments. The
covered lengths of the distal Talent endograft range from
110 mm (largest diameter) to 114 mm (smallest diameter).
Talent Thoracic Valor Trial. The Valor Trial was a
prospective multicenter nonrandomized investigation of
the safety and efficacy of the Talent Thoracic Stent Graft in
patients with thoracic aneurysms. Retrograde type A aortic
dissection developed in three patients (1.5%), the cause of
which was unknown but might have been related to the
stiffness of the five peaks of the uncovered proximal stent.
The proximal portion of the next-generation Valiant device
is much more flexible and no longer contains a longitudinal
connecting bar. The proximal uncovered stent has been
Fig 1. Left, Original Gore TAG device with longitudinal spine.
Right, Current Gore TAG device.modified from five to eight peaks, which are thinner andexert less force on the aortic wall. Longer devices up to 200
mm will also be available with the Valiant device. The
Talent thoracic device was approved on the Coil Trac
delivery system and was switched after approval to the
Xcelerant delivery platform, which is much more flexible
and tracks easier through the vasculature.
COOK ZENITH TX2 STENT GRAFT
Device construct. The Zenith TX2 TAA Endovascu-
lar Graft is a two-piece or one-piece cylindrical endovascu-
lar graft. The two-piece system consists of a proximal main
Fig 2. Deployment of the Gore TAG device from the central
portion to each end.
Fig 3. Talent thoracic device.body component and overlapping distal main body com-
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main body component or a proximal main body compo-
nent, without the use of a distal main body component.
The proximal main body components can be either tapered
(by 4 mm) or nontapered. The stent grafts are constructed
of full-thickness woven polyester fabric sewn to self-
expanding stainless steel Cook-Z stents with braided poly-
ester and monofilament polypropylene sutures. For added
fixation, the covered stent at the proximal end of the
proximal main body component (tapered and non-tapered)
and one-piece main body component contains barbs placed
at a 2-mm stagger, which protrude through the graft
material (Fig 4). The bare stent at the distal end of the distal
main body component and one-piece main body compo-
nent also contains barbs (Fig 4). The number of barbs per
covered or uncovered stent depends on component diam-
eter, such that barbed stents on 28- to 40-mm diameter
components contain 12 barbs, and barbed stents on
42-mm diameter components contain 14 barbs. Depend-
ing on component diameter, the main body components
are deployed from either a 20 F or 22F H&L-B One-Shot
Introduction System. All 28- to 34-mm diameter compo-
nents are deployed using a 20F system, and all 36- to
42-mm diameter components are deployed using a 22F
system.
Since commercial release, a design modification to the
Fig 4. Cook TX2 device.device has occurred. A change of the trigger wire confor-mation allows the device to be constrained at the proximal
stent to allow for better opposition to aortic wall in the
curvature of the arch called Pro-form (Fig 5).
Starz-TX2 Clinical Trial. The STARZ-TX2 Clinical
Trial was a nonrandomized, controlled, multicenter study
that evaluated the safety and effectiveness of the Zenith
TX2 TAA Endovascular Graft in the elective treatment of
patients with descending thoracic aortic aneurysms or ul-
cers, compared with open surgical repair.
DEVICE COMPARISONS
Data from the three trials for the TAG, Talent, and TX2
trials each proved safety and efficacy and led to FDA ap-
proval of these devices. No comparative data exists regard-
ing the use of these devices for thoracic aneurysms; how-
ever, there are some differences between the trials that bear
discussion. The TAG study 99-01 was the first to be com-
pleted through 5 years, and the data regarding the long-
term outcomes of this device now exist. Because of the later
start of the Talent and TX2 device trials, we only have
1-year data to evaluate.
Device construct is clearly different between the de-
vices, with one made up of ePTFE and two constructed
from different thicknesses of polyester. Despite these dif-
ferences, the devices have had similar rates of success. The
original Gore TAG device in 99-01 showed the highest risk
of aneurysm sac enlargement of all the devices. A high rate
of enlargement of aneurysm sac diameter was also seen with
the original Gore Excluder AAA device. Changes in the
device construct adding a low permeability layer to the
device seems to have eliminated this issue as a risk of
aneurysm sac enlargement because the risk was reduced to
4.5% at 4 years in the TAG 03-03 study.
Access-related issues are clearly a problem with thoracic
devices. The higher percentage of women with thoracic
aneurysms only confounds this issue. Each device requires
Fig 5. Cook TX2 Pro-form modification.different diameters for introduction. Although the Gore
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required for introduction. The Gore TAG 26- and 28-mm
device requires a 20F sheath. The 31- and 34-mm device
requires a 22F sheath, and the 37-, 40-, and 45-mm device
requires a 24F sheath. The Talent device is preloaded in its
own delivery sheath, and the device diameter is based
measured by the outer diameter of the device and not by
conventional sheath terminology, which implies the inner
diameter. The 22- to 32-mm Talent devices have a 22F
outer diameter, the 34- to 40-mm devices have a 24F outer
diameter, and the 42- to 46-mm devices have a 25F outer
diameter. The 28- to 34-mm TX2 device comes in a 20F
sheath delivery system, and the 36- to 42-mm TX2 device
comes in a 22F sheath delivery system. So which device has
the smallest delivery system? It really depends on the graft
diameter (Table). Despite differences in delivery profile, all
of the three devices required conduits in 9% to 21% of
patients.
The neck required for treatment in the studies also
differed. The Gore TAG and Talent Thoracic device both
required 20 mm of neck length proximally and distally,
whereas the Cook TX2 device required a 30-mm neck
distance. This difference clearly will expand the amount of
patients able to be treated according to the instructions for
use with the Talent and TAG devices compared with the
TX2 device.
The sizing criterion for device choices differs, with the
Gore TAG trial using inner aortic diameters and the Talent
and TX2 trials using outer aortic diameter. This difference
may allow for larger aneurysms to be treated with TAG
devices, depending on the aortic wall thickness.
There is marked variation in the delivery systems of the
three commercial devices currently in use:
● The Gore TAG device has not manufactured within a
sheath and is a very flexible design. TheGoreTAGdevice
is wrapped in a PTFE sleeve that does not connect to the
olive tip of the delivery catheter. The tortuous arch may
cause difficulty in advancement as the two components
separate in bends. Gore modified the olive tip after ap-
proval to minimize this problem.
● The Talent thoracic device has a very stiff design.3 It
was approved on the Coil Trac delivery system that
held the distal stent graft in a cup. The original Coil
Table. Device diameters based on labeled diameters from
device instructions for use
Graft type Graft diameter (mm) Entry diameter (mm)
Talent 22 to 32 7.3
Gore TAG 26, 28 7.6
Cook TX2 28, 30, 32, 34 7.7
Talent 34, 36, 38, 40 8.0
Talent 42, 44, 46 8.3
Gore TAG 31, 34 8.3
Cook TX2 36, 38, 40, 42 8.7
Gore TAG 37, 40, 45 9.2Trac delivery system had a transition in stiffness at thecup holding the device allowing for potential kinking
of the delivery system at this point. The Talent thoracic
device now comes on the Xcelerant delivery system,
which allows for more controlled delivery and less
friction with deployment.
● The Cook TX2 device originally came on a nonbraided
sheath that would kink when taken through bends in
anatomy. The device was switched during the trial to a
hydrophilic braided version that has improved deliver-
ability. The current TX2 sheath also has added a Cap-
tor hemostasis valve that vastly diminished blood loss
around the wire during the procedure.
Distal migration during deployment can occur due to a
“windsock” phenomenon. This phenomenon is created by
arterial flow pushing on only a partially opened stent graft.
This problem was most pronounced when using home-
made devices. Lowering the mean arterial pressure during
deployment or inducing asystole with adenosine has been
used to minimize the risk of windsock-induced migra-
tion.4,5 More recent reports have shown the value of over-
drive atrial pacing at controlling the aortic forces for accurate
device deployment.6 Design modifications to commercial de-
vices have attempted to eliminate or minimize this problem.
For example, the Gore Excluder starts to deploy from the
midpoint of the device and progresses simultaneously both
proximally and distally. This design lessens but does not
eliminate problems from windsock. The Gore TAG and
Talent thoracic device instructions for use both suggest
lowering the mean arterial pressure during device deploy-
ment to improve accuracy of deployment. Fixation of the
device to the delivery systemmay avoid distal migration and
is incorporated into the Cook thoracic design.7 The Talent
thoracic device has reported problems with misaligned
asymmetric deployment of the proximal uncovered stent
after U.S. approval.8 The exact cause is unknown but
Medtronic is now working on approval of a tip capture
design to better control delivery of the proximal uncovered
stent.
Alignment to the seal zone in tortuous anatomy and
narrow radius of curvature is a limitation to all three de-
vices. The Gore TAG device has a wide sealing cuff that
limits flexibility and may not conform to the proximal seal
zone in tight bends. The covered scalloped ends, when not
opposed to the aortic wall, will force flow behind the
device, which can lead to compromised sealing or increased
stress on the device. There have been case reports of TAG
device collapse after not conforming to the radius of the
arch; however, reported cases have been in traumatic rup-
tured aortas used outside of the instructions for use.8-11
Several theories have been proposed to explain this occur-
rence, including excessive oversizing at the proximal seal
zone as well as flow behind the covered scallops leading to
accelerated mechanical fatigue of the metal.
Gore recently began a study of the conformable TAG
device, which contains modifications made to improve
apposition in the proximal seal zone and has removed the
covered scallops. The Talent device has a proximal uncov-
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version is very stiff with five peaks. The Talent device is the
only trial to report acute type A aortic dissection after
treatment in the U.S. Investigational Device Exemption
(IDE) trials. This may be due to the stiff design of the
current device. The next-generation Valiant device has 8
peaks uncovered proximally with a much less rigid design.
The Cook TX 2 device also has conformability issues in
narrow arches. The Pro-formmodification to the device has
recently been introduced to force the device to better fit
against the proximal seal zone.
Device integrity is a common concern to all devices in
the long term. This is the reason lifelong surveillance is
necessary. Metal fractures have been identified in all three
available thoracic endovascular devices. Fracture of the
longitudinal nitinol wire in both the Gore thoracic TAG
device and Talent thoracic device has occurred in up to 30%
of implants.12 Modifications to the design of the Gore
thoracic device to eliminate the longitudinal nitinol wire
were implemented after identification of this complication
in the Gore 99-01 study. Longitudinal strut fracture has
also been seen with the Talent device and is no longer a part
of the next-generation Valiant device. As the aortic forces
exerted on thoracic endoluminal grafts are studied and
better understood, design changes may eliminate material
fatigue.
CONCLUSIONS
Since 2005, we have seen introduction of three endo-
vascular devices to treat descending thoracic aneurysms.
The devices have all had success compared with open
repair. No device is perfect, and each has unique strengths
and limitations. As we learn from the current devices, newer
designs and modifications to current devices will be created
to hopefully expand the application of these devices to a
broader patient population.REFERENCES
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